

# TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

Julie van der Zee,<sup>1,2†</sup> Ilse Gijssels,<sup>1,2†</sup> Sara Van Mossevelde,<sup>1,2,3</sup> Federica Perrone,<sup>1,2</sup> Lubina Dillen,<sup>1,2</sup> Bavo Heeman,<sup>1,2</sup> Veerle Bäumer,<sup>1,2</sup> Sebastiaan Engelborghs,<sup>2,4</sup> Jan De Bleecker,<sup>5</sup> Jonathan Baets,<sup>1,2,3</sup> Ellen Gelpi,<sup>6</sup> Ricardo Rojas-García,<sup>7</sup> Jordi Clarimón,<sup>7,8</sup> Alberto Lleó,<sup>7,8</sup> Janine Diehl-Schmid,<sup>9</sup> Panagiotis Alexopoulos,<sup>9</sup> Robert Pernecky,<sup>9,10,11</sup> Matthias Synofzik,<sup>12,13</sup> Jennifer Just,<sup>12,13</sup> Ludger Schöls,<sup>12,13</sup> Caroline Graff,<sup>14,15</sup> Håkan Thonberg,<sup>14,15</sup> Barbara Borroni,<sup>16</sup> Alessandro Padovani,<sup>16</sup> Albena Jordanova,<sup>1,2,17</sup> Stayko Sarafov,<sup>18</sup> Ivailo Tournev,<sup>19</sup> Alexandre de Mendonça,<sup>20,21</sup> Gabriel Miltenberger-Miltényi,<sup>20,21</sup> Frederico Simões do Couto,<sup>20,21</sup> Alfredo Ramirez,<sup>22,23,24</sup> Frank Jessen,<sup>22,24,25</sup> Michael T. Heneka,<sup>25,26</sup> Estrella Gómez-Tortosa,<sup>27</sup> Adrian Danek,<sup>28,29</sup> Patrick Cras,<sup>2,3</sup> Rik Vandenberghe,<sup>30,31</sup> Peter De Jonghe,<sup>1,2,3</sup> Peter P. De Deyn,<sup>2,4</sup> Kristel Slegers,<sup>1,2</sup> Marc Cruts,<sup>1,2</sup> Christine Van Broeckhoven,<sup>1,2\*</sup> and Belgian Neurology Consortium and European Early-Onset Dementia Consortium<sup>1†</sup>

<sup>1</sup>Center for Molecular Neurology, VIB, Antwerp, Belgium; <sup>2</sup>Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; <sup>3</sup>Department of Neurology, Antwerp University Hospital, Edegem, Belgium; <sup>4</sup>Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium; <sup>5</sup>Department of Neurology, University Hospital Ghent and University of Ghent, Ghent, Belgium; <sup>6</sup>Neurological Tissue Bank of the Biobanc - Hospital Clinic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; <sup>7</sup>Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>8</sup>Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; <sup>9</sup>Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany; <sup>10</sup>Neuroepidemiology and Ageing Research Unit, School of Public Health, The Imperial College of Science, Technology and Medicine, London, UK; <sup>11</sup>West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London TW8 8DS, UK; <sup>12</sup>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and Centre of Neurology, Tübingen, Germany; <sup>13</sup>German Research Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; <sup>14</sup>Department of Neurobiology, Care Sciences and Society (NVS), KI-Alzheimer Disease Research Center, Karolinska Institutet, Stockholm, Sweden; <sup>15</sup>Department of Geriatric Medicine, Genetics unit, Karolinska University Hospital, Stockholm, Sweden; <sup>16</sup>Neurology Unit, University of Brescia, Brescia, Italy; <sup>17</sup>Department of Biochemistry, Molecular Medicine Center, Medical University-Sofia, Sofia, Bulgaria; <sup>18</sup>Department of Neurology, Medical University-Sofia, Sofia, Bulgaria; <sup>19</sup>Department of Cognitive Science and Psychology, New Bulgarian University, Sofia, Bulgaria; <sup>20</sup>Hospital Santa Maria, Lisbon, Portugal; <sup>21</sup>Faculty of Medicine and Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal; <sup>22</sup>Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany; <sup>23</sup>Institute of Human Genetics, University of Bonn, Bonn, Germany; <sup>24</sup>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany; <sup>25</sup>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; <sup>26</sup>Clinical Neuroscience Unit, Department of Neurology, University of Bonn, Bonn, Germany; <sup>27</sup>Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain; <sup>28</sup>Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany; <sup>29</sup>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; <sup>30</sup>Department of Neurosciences, Faculty of Medicine, KU Leuven, Leuven, Belgium; <sup>31</sup>Department of Neurology, University Hospitals Leuven, Leuven, Belgium

Communicated by Lars Bertram

Received 10 October 2016; accepted revised manuscript 15 December 2016.

Published online 23 December 2016 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.23161

Additional Supporting Information may be found in the online version of this article.

<sup>†</sup>These authors contributed equally to this work and are shared first author.

<sup>‡</sup>The Belgian Neurology (BELNEU) consortium and European Early-Onset (EU EOD) consortium side authors are listed in the Acknowledgements.

Contract grant sponsors: Belgian Science Policy Office Interuniversity Attraction Poles Program; Flemish Government (Flanders Impulse Program on Networks for Dementia Research, Methusalem Excellence Program); the Research Foundation Flanders (FWO); the University of Antwerp Research Fund; Fondazione Cassa di Risparmio di Pistoia e Pescia (grants 2014.0365, 2011.0264, and 2013.0347); the Cassa di Risparmio di Firenze (grant 2014.0310); Fondo di Ateneo 2014; Ricerca Corrente; Italian Ministry of Health; Else Kröner-Fresenius-Stiftung (EKMS 018); Swedish Brain Power; Swedish Research Council (grant numbers 521-2010-3134, 2015-02926); Gun and Bertil Stohne; Gamla tjanarinnor; Demensfonden; Sweden Alzheimer Foundation (AF-556561); King Gustaf V and Queen Victoria's Foundation of Freemasons; StratNeuro at Karolinska Institute (KI).

**ABSTRACT:** We investigated the mutation spectrum of the TANK-Binding Kinase 1 (TBK1) gene and its associated phenotypic spectrum by exonic resequencing of TBK1 in a cohort of 2,538 patients with frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or FTD plus ALS, ascertained within the European Early-Onset Dementia Consortium. We assessed pathogenicity of predicted protein-truncating mutations by measuring loss of RNA expression. Functional effect of in-frame

\*Correspondence to: Christine Van Broeckhoven, Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, University of Antwerp – CDE, Universiteitsplein 1, Antwerp B-2610, Belgium. E-mail: christine.vanbroeckhoven@molgen.vib-ua.be

© 2016 The Authors. \*\* Human Mutation published by Wiley Periodicals, Inc.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

amino acid deletions and missense mutations was further explored in vivo on protein level and in vitro by an NF $\kappa$ B-induced luciferase reporter assay and measuring phosphorylated TBK1. The protein-truncating mutations led to the loss of transcript through nonsense-mediated mRNA decay. For the in-frame amino acid deletions, we demonstrated loss of TBK1 or phosphorylated TBK1 protein. An important fraction of the missense mutations compromised NF $\kappa$ B activation indicating that at least some functions of TBK1 are lost. Although missense mutations were also present in controls, over three times more mutations affecting TBK1 functioning were found in the mutation fraction observed in patients only, suggesting high-risk alleles ( $P = 0.03$ ). Total mutation frequency for confirmed TBK1 LoF mutations in the European cohort was 0.7%, with frequencies in the clinical subgroups of 0.4% in FTD, 1.3% in ALS, and 3.6% in FTD-ALS.

Hum Mutat 38:297–309, 2017. Published 2016 Wiley Periodicals, Inc.\*\*

**KEY WORDS:** TANK-Binding Kinase 1; TBK1; frontotemporal dementia; FTD; amyotrophic lateral sclerosis; ALS; mutations; NF $\kappa$ B luciferase reporter assay

## Introduction

Multiple lines of evidence have now strongly established that frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) share a common molecular etiology and are part of a disease continuum. Up to 50% of frontotemporal dementia (FTD) patients develop signs of motor neuron disease (MND) at some stage in the disease course with about 15% meeting the diagnostic criteria of ALS; conversely, over 30% of ALS patients show signs of FTD [Lomen-Hoerth et al., 2002]. Neuropathologically, the majority of these patients display accumulation of TDP-43 aggregates in affected brain regions and motor neurons. Furthermore, common genetic factors underlying FTLD and ALS, such as the chromosome 9 open-reading frame 72 (*C9orf72*, MIM# 614260) [DeJesus-Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al., 2012], valosin containing protein (*VCP*, MIM# 601023) [Watts et al., 2004; Johnson et al., 2010], TAR DNA-binding protein (*TARDBP*, MIM# 605078) [Kabashi et al., 2008; Sreedharan et al., 2008; Borroni et al., 2009; Gelpi et al., 2014], and Fused in sarcoma RNA-binding protein (*FUS*, MIM# 137070) [Kwiatkowski et al., 2009; Van Langenhove et al., 2010] genes, are key pathological genes in both diseases. Of these, the G<sub>4</sub>C<sub>2</sub> repeat expansion in *C9orf72* is the most frequent genetic cause of the FTD–ALS spectrum, accounting for up to 29%, 50%, and 88% of FTD, ALS, and FTD-ALS patient series, respectively [Cruts et al., 2013].

Also, loss-of-function (LoF) of the TANK-binding kinase 1 (*TBK1*, MIM# 604834) was causally associated with ALS and FTD [Cirulli et al., 2015; Freischmidt et al., 2015; Gijselinck et al., 2015; Le Ber et al., 2015; Pottier et al., 2015; Williams et al., 2015]. TBK1 is a multifunctional kinase regulating a number of cellular processes, including the innate immune system and inflammation, autophagy, and cell proliferation, by phosphorylating a wide range of substrates [Clément et al., 2008; Pilli et al., 2012; Larabi et al., 2013]. Of interest, these substrates include optineurin (OPTN) and p62, two autophagic proteins that are also genetically implicated in the FTD-ALS spectrum. Furthermore, TBK1 homodimerization and

autophosphorylation at the serine 172 residue is necessary for its activation. One of the downstream effects of TBK1 activation is the upregulation of interferon (IFN)-stimulated genes by activation of the nuclear factor of the kappa light polypeptide gene enhancer in B-cells (NF $\kappa$ B) complex.

Frameshift, out-frame, splice-site, and nonsense mutations generating premature termination codons (PTC) in *TBK1* have been demonstrated to result in LoF through loss of mutant transcript and protein [Freischmidt et al., 2015; Gijselinck et al., 2015; Pottier et al., 2015]. In addition to these clear pathogenic mutations, a small number of in-frame single amino acid deletions have been found, some of which cosegregated with disease that led to loss of protein, whereas others did not [Freischmidt et al., 2015; Gijselinck et al., 2015]. Furthermore, numerous rare missense mutations have been identified, in both patient and control subjects [Cirulli et al., 2015; Freischmidt et al., 2015; Gijselinck et al., 2015; Le Ber et al., 2015; Pottier et al., 2015; Williams et al., 2015]. Prediction of their pathogenic effect may be ambiguous, certainly in the absence of supportive cosegregation. One report was able to demonstrate functional deficits for a number of missense mutations by testing their effect in vitro on the IFN $\beta$  pathway and on the interaction with adaptor protein OPTN [Freischmidt et al., 2015], indicating that at least some missense mutations may be disease-causing.

In the previous study, we reported the identification of *TBK1* LoF mutations in a Belgian discovery cohort of FTD ( $n = 460$ ), FTD-ALS ( $n = 22$ ), and ALS ( $n = 147$ ) patients, yielding mutation frequencies of 1.1% in FTD, 3.4% in ALS patients, and 4.5% in FTD-ALS [Gijselinck et al., 2015]. In the present study, we expanded the *TBK1* genetic screen with a European replication cohort of 1,755 patients with FTD ( $n = 1,271$ ), ALS ( $n = 407$ ), or FTD-ALS ( $n = 77$ ). In addition to the protein-truncating mutations that led to loss of transcript, we also assessed the pathogenic effect of in-frame deletions and missense mutations on protein level and function, the latter using an in vitro luciferase assay measuring the effect of mutant *TBK1* on NF $\kappa$ B activation in the IFN pathway. Taken together, this study reports on the mutation frequency and mutation spectrum of *TBK1* in an extended European study population of 2,538 patients with FTD ( $n = 1,873$ ), ALS ( $n = 554$ ), or FTD-ALS ( $n = 111$ ).

## Materials and Methods

### European Study Population

The patient and control cohorts under study were ascertained through the Belgian Neurology (BELNEU) consortium or the European Early-Onset Dementia (EU EOD) consortium, as described in previous studies [van der Zee et al., 2013, 2014; Gijselinck et al., 2015; Van Mossevelde et al., 2015]. DNA and medical/demographic information was included on 2,538 patients, comprising 1,873 patients diagnosed with FTD, 111 with concomitant FTD-ALS, and 554 patients with ALS. Patients originated from Austria, Belgium, Bulgaria, Czech Republic, Germany, Greece, Italy, Portugal, Spain, and Sweden (Table 1). Patients were evaluated and diagnosed with FTD according to the Lund and Manchester group criteria [Neary et al., 1998], and for ALS, according to the revised El Escorial criteria [Brooks et al., 2000]. Clinical diagnoses of behavioral variant FTD (bvFTD) was based on the international consensus criteria by Rascovsky et al. (2011), and of primary progressive aphasia (PPA) on the classification of Gorno-Tempini et al. (2011). A positive family history was defined for index patients with first- or second-degree relatives with symptoms of dementia or MND. In the FTD group, 34% (635/1,873) had a positive family history, in the FTD-ALS group

**Table 1. Descriptives of the EU EOD Patient Cohorts**

EU EOD cohorts and PI	FTD 1,873	FTD-ALS 111	ALS 554	Total 2,538
Belgium ( <i>n</i> = 783)				
Van Broeckhoven (= Belgian discovery cohort)	460	22	147	629
Van Broeckhoven	142	12	0	154
Spain ( <i>n</i> = 548)				
Clarimon	76	7	92	175
Pastor	126	3	12	141
Ruiz	95	0	0	95
Sanchez	53	8	0	61
Gelpi	12	8	16	36
Gómez-Tortosa	38	2	0	40
Italy ( <i>n</i> = 442)				
Borroni	165	12	24	201
IRCCS Brescia 01	110	0	0	110
Nacmias	74	5	0	79
Frisoni	48	1	0	49
Fabrizi	0	2	1	3
Germany ( <i>n</i> = 317)				
Diehl-Schmid	153	3	0	156
Ramirez	60	0	21	81
Synofzik	0	0	78	78
Danek	1	1	0	2
Portugal ( <i>n</i> = 195)				
Mendonça	130	4	0	134
Santana	57	4	0	61
Bulgaria ( <i>n</i> = 134)				
Jordanova	0	2	132	134
Sweden ( <i>n</i> = 60)				
Graff	55	4	1	60
Czech Republic ( <i>n</i> = 30)				
Matěj	18	8	4	30
Greece ( <i>n</i> = 26)				
Fraidakis	0	1	25	26
Austria ( <i>n</i> = 3)				
Kovacs	0	2	1	3

Of the 783 Belgian patients and 1,074 Belgian controls included in the present European study population, *TBK1* mutation screening data on 629 patients and 1,044 control individuals were previously published as part of the Belgian discovery cohort [Gijssels et al., 2015; Van Mossevelde et al., 2015]. Novel patients and control subjects reported in this study are part of the European replication cohort. Together, the Belgian discovery cohort and the European replication cohort constitute the European study population. P.I., principle investigator.

29% (32/111) and in the ALS group 8% (46/554). As control group, 2,183 age- and origin-matched European control individuals, with no personal or family history of neurodegenerative or psychiatric diseases, were included.

Of the 783 Belgian patients and 1,074 Belgian controls included in the present European study population (Table 1), *TBK1* mutation screening data on 629 patients and 1,044 control individuals was generated and published as part of the Belgian discovery cohort [Gijssels et al., 2015; Van Mossevelde et al., 2015]. Novel patients (*n* = 1,755) and control subjects (*n* = 1,109) reported in this study are part of the European replication cohort. Together, the Belgian discovery cohort and the European replication cohort constitute the European study population (Table 1).

For all participants, informed consent for participation in the genetic studies was obtained according to sampling protocols that were approved by the local Ethics Committees of the collaborating medical centers. The protocols for the genetic studies were approved by the Ethics Committee of the University of Antwerp, Belgium.

## Exonic Resequencing

All coding exons of *TBK1* (NM\_013254.3) were sequenced on a MiSeq platform using the MiSeq V2 chemistry (Illumina, San Diego, CA), except for exon 4, which was sequenced by Sanger

sequencing using the BigDye® Terminator Cycle Sequencing kit v3.1 (Applied Biosystems, Foster City, CA). Detailed technical procedures were previously described [Gijssels et al., 2015].

Reported variants follow cDNA numbering according to reference sequence NM\_013254.3. In addition, for intronic variants, the genomic reference sequence NC\_000012.12 was used. Nucleotide positions refer to cDNA sequence and nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. Protein numbering is given according to reference sequence NP\_037386.1. Variants identified in this study have been submitted to the Alzheimer Disease & Frontotemporal Dementia Mutation Database (AD&FTDMDB, <http://www.molgen.vib-ua.be/FTDMutations>) and Locus Specific Database [Cruts et al., 2012].


## Transcript Analysis

When the required biomaterials were available, transcript analysis was performed for patients with a *TBK1* mutation (Fig. 1). For the c.288delT (p.Val97Phefs\*2) and the c.1340+1G>A (p.Ala417\*) carriers, total RNA was isolated from whole blood using the PAXgene Blood RNA kit (PreAnalytiX; Qiagen, Valencia, CA) in accordance with the manufacturer instructions. First-strand cDNA was synthesized from total RNA with random hexamers primers using the Invitrogen ThermoScript RT-PCR kit (Invitrogen, Carlsbad, CA). For transcript analysis of the c.235\_237delACA (p.Thr79del) and c.379C>T (p.Arg127\*) carriers, total RNA was extracted from blood mononuclear cells (p.Arg127\*) or frontal cortical brain tissue (p.Thr79del) from the carriers. First-strand cDNA was synthesized with oligodT and random hexamers primers, using the SuperScript III First-Strand Synthesis System for RT-PCR kit (Invitrogen). cDNA of these samples was amplified using the universal amplification protocol (Applied Biosystems). For p.Val97Phefs\*2, exon 4 was amplified with flanking PCR primers positioned in exons 3 and 5. For p.Ala417\*, predicted to lead to exon 11 skipping, cDNA was amplified with primers positioned in exons 10 and 13. For p.Arg127\*, exon 5 was amplified with PCR primers in exon 3 and exon 6. All PCR products were Sanger sequenced to evaluate whether the mutant transcript was present based on the coding mutation and whether alternative transcripts were formed. Genotypes of cDNA sequences were compared with genomic DNA sequences. Primer sequences will be provided upon request.

For quantification of the transcripts created by the p.Thr79del mutation, semiquantitative real-time PCR (qPCR) was performed using SYBR Green assays on the ViiA™ 7 Real-Time PCR System (Applied Biosystems). A qPCR amplicon was designed, spanning exons 19 and 20 (primers 5'-CATGACCCCAATTATCCAAGTTC-3' and 5'-CATCTCTTCCTTAATTCTTCATACCA-3'), detecting the *TBK1* ref gene transcript variant NM\_013254 using Primer-Express Software (Applied Biosystems) and quantified against three housekeeping genes, *HPRT*, *GAPDH*, and *SDHA*. Relative expression levels were calculated by comparing normalized quantities between patient and control samples using qbase+ software (Biogazelle, Ghent, Belgium).

## Protein Analysis

Protein lysates from the *TBK1* p.Thr79del carrier and control frontal cortex tissue were prepared for Western blot with 0.1% RIPA and sonicated on ice, cleared at 20,000 g for 15 min at 4°C and supernatants used for immunoblotting (Fig. 1). Protein concentrations were measured by a BCA assay (Pierce, Rockford, IL), and 30 µg of



**Figure 1.** Transcript and protein analysis of *TBK1* LoF and single amino acid deletion mutations. **A:** gDNA and cDNA sequence traces around the c.288delT (p. Val97Phefs\*2) mutation, showing reduced expression of the mutant transcript on cDNA extracted from blood. **B:** gDNA and cDNA sequence traces around the c.379C>T (p.Arg127\*) mutation, showing the absence of the mutant transcript on cDNA extracted from blood. **C:** Sizing of cDNA fragments generated with primers in *TBK1* exon 10 and exon 13 of the c.1340+1G>A (p.Ala417\*) carrier on cDNA extracted from blood. Sequence traces from the low-expressed aberrant transcript demonstrates skipping of exon 11. **D:** Transcript and protein analysis on brain frontal cortex from the c.235\_237delACA (p.Thr79del) carrier and four age-matched control brains. The graph on the left shows the relative expression in the patient sample (blue) compared with the control samples (black) measured by quantitative real-time PCR (qRT-PCR). In the middle, Western blot analysis is shown of protein extracts from the patient carrier compared with control individuals. The upper band represents TBK1 (84 kDa) and the lower band represents the housekeeping protein GAPDH (37 kDa). The graph on the right shows the quantification in the patient sample (blue) and control samples (black) of the TBK1 signal normalized to the signal of GAPDH. Error bars represent the SD. **E:** Western blot analysis of phosphorylated TBK1 (Ser172, p-TBK1) (upper band, 84 kDa) in HEK293T cells overexpressing the in-frame single amino acid deletions (p.Thr79del, p.Asp167del, and p.Glu643del) compared with wild type, relative to GAPDH (lower band, 37 kDa). Mock and kinase dead (p.Ser172Ala, KD) were used as negative control. cDNA numbering according to reference sequence NM\_013254.3, in addition, for intronic variants, the genomic reference sequence NC\_000012.12 was used. Nucleotide positions refer to cDNA sequence and nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. Protein numbering according to reference sequence NP\_037386.1.



**Table 2. *TBK1* Predicted LoF Mutations in the European Study Population**

cDNA	Predicted protein	FTD <i>n</i> = 1,873	FTD-ALS <i>n</i> = 111	ALS <i>n</i> = 554	Cohorts of the European study population
Protein-truncating mutations leading to loss of transcript					
c.4C>T	p.Gln*2	1			Belgian discovery cohort
c.86delA	p.Lys29Argfs*15	1			European replication cohort
c.288delT	p.Val97Phefs*2			1	European replication cohort
c.349C>T	p.Arg117*		1		European replication cohort
c.379C>T	p.Arg127*			1	European replication cohort
c.992+1G>T	p.Gly272..Thr331del	1			Belgian discovery cohort
c.1192delT	p.Ser398Profs*11			1	Belgian discovery cohort
c.1335G>A	p.Trp445*	1			European replication cohort
c.1340+1G>A	p.Ala417*	1			European replication cohort
c.1385_1388delCAGA	p.Thr462Lysfs*3		1		European replication cohort
c.1551_1552insTT	p.Ser518Leufs*32			1	Belgian discovery cohort
In-frame deletions leading to loss-of-protein or protein function					
c.235_237delACA	p.Thr79del		1		European replication cohort
c.499_501delGAT	p.Asp167del			1	Belgian discovery cohort
c.1927_1929delGAA	p.Glu643del	3	1	2	Belgian discovery cohort
Predicted in-frame deletions with unknown effect					
c.228+1G>A	p.Lys30..Glu76del			1	European replication cohort
c.992+4_992+7delAGTA	p.Gly272..Thr331del		1		European replication cohort

All listed mutations were absent from 2,183 screened control individuals and dbSNP build 138. The respective cohorts of the European study population in which mutations were identified are indicated in the last column. Mutations and carriers identified in the Belgian discovery cohort were previously published by our group [Gijssels et al., 2015; Van Mossevelde et al., 2015]. Novel mutations and carriers reported in this study are part of the European replication cohort. cDNA numbering was according to the reference sequence NM\_013254.3. In addition, for intronic variants, the genomic reference sequence NC\_000012.12 was used. Nucleotide positions refer to cDNA sequence and nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. Protein numbering according to reference sequence NP\_037386.1.

protein were separated on 4%–12% Nupage Bis–Tris gels (Invitrogen), electroblotted onto a PVDF membrane (Hybond P; Amersham Biosciences, GE Healthcare, Little Chalfont, UK), and probed with a monoclonal antibody against *TBK1* (Abcam, Cambridge, MA; 1:1,000, 84 kDa). Immuno-detection was performed with specific secondary antibodies conjugated to horseradish peroxidase and the ECL-plus chemiluminescent detection system (Amersham Biosciences). *TBK1* signal intensities were quantified against GAPDH (Genetex, Irvine, CA; 1:10,000, 37 kDa), using ImageQuantTL software (GE Healthcare Life Sciences, Little Chalfont, UK).

### ***TBK1* Cloning and Overexpression in HEK293T Cells**

*TBK1* plasmids containing a missense mutation or a single amino acid deletion were generated by in vitro mutagenesis using the KAPA HiFi HotStart DNA polymerase (Kapa Biosystems, Wilmington, MA) starting from the *TBK1* wild-type gateway pDONR vector (NM.013254.3) (GeneCopoeia, Rockville, MD). The p.Ser172Ala mutant (kinase dead) generating a *TBK1* protein lacking kinase activity, and the mock plasmid containing no *TBK1*, were used as negative controls. The gateway-compatible pCR3 vector (Life Technologies, Carlsbad, CA) was used as expression vector.

Each *TBK1* plasmid was transiently transfected in HEK293T cells using Lipofectamine 2000 (Life Technologies). Protein lysates of these *TBK1* overexpression cells were used for Western blotting with an antibody against *TBK1* (Abcam; 1:1,000, 84 kDa) and GAPDH (Genetex; 1:10,000, 37 kDa). Autophosphorylation activity of the single amino acid deletions was determined by Western blot analysis with p-*TBK1* antibody (phospho S172) (Abcam; 1:500, 84 kDa).

### **NFκB Reporter Assay**

Each *TBK1* plasmid was transiently transfected in human embryonic kidney cells (HEK293T) using X-tremeGENE 9 DNA Transfection Reagent (Sigma–Aldrich, St Louis, MO), together with the

NFκB luciferase reporter vector (Affymetrix, Santa Clara, CA) containing an inducible Firefly luciferase reporter gene to monitor the activation of the NFκB signal transduction pathway and the pTK–GLuc plasmid that encodes the Gaussia luciferase gene (New England Biolabs, Ipswich, MA) for normalization. Firefly luciferase activities ( $LA_F$ ) and Gaussia luciferase activities ( $LA_G$ ) were measured in fivefold by the use of a Dual-Glo Luciferase Assay System (Promega, Madison, WI) and a BioLux Gaussia Luciferase Assay Kit (New England Biolabs) on a Veritas Microplate Luminometer (Promega). To correct for transfection efficiency and DNA uptake, the relative luciferase activity (RLA) was calculated as  $RLA = LA_F/LA_G$ . This experiment was repeated three times. Differences in relative luciferase activities between mutant and wild-type *TBK1* plasmids were calculated by a linear mixed model using the statistical packages lme4 and nlme in R and corrected for multiple testing using Bonferroni correction.

### **Neuropathology of *TBK1* p.Thr79del Carrier**

Neuropathological work-up was performed at the Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS (Barcelona, Spain), according to standardized procedures. In brief, fragments of frontal cortex and cerebellum were immediately frozen at  $-80^{\circ}\text{C}$ , whereas the remaining brain tissue was fixed in 10% buffered formaldehyde solution for 4 weeks. For histopathological evaluation, 5  $\mu\text{m}$  thick sections were cut from formalin-fixed and paraffin-embedded tissue from multiple brain areas including frontal, temporal, parietal and occipital cortices, motor cortex, anterior cingulate gyrus, anterior and posterior basal ganglia, anterior, medial and posterior thalamic nuclei, hippocampus and parahippocampal gyrus, amygdala, n. basalis Meynert, midbrain, pons, medulla oblongata, cerebellar vermis, and dentate nucleus, as well as cervical, thoracic, and lumbar segments of spinal cord.

Sections were stained with hematoxylin-eosin, Luxol fast blue, and for immunohistochemistry using the following monoclonal (mc) and polyclonal (pc) primary antibodies on an automated

immunostainer (DAKO autostainer plus; DAKO, Glostrup, Denmark) after heat- or chemically induced epitope retrieval with formic acid: anti-bA4-amyloid (DAKO; mc, clone 6F/3D, dilution 1:400), antiphosphorylated tau (Thermo Scientific, Rockford, IL; mc, clone AT8, dilution 1:200), antiubiquitin (DAKO; pc, dilution 1:400), anti-alpha-synuclein (Novocastra, Newcastle, UK; mc, clone KM51, dilution 1:500), anti-TDP-43 (Abnova, Taipei, Taiwan; mc, clone 2E2-D3, dilution 1:500), antineurofilaments (Novocastra; clone RT97, dilution 1:800), anti-RD3 (Millipore, Temecula, CA; mc, clone 8E6/C11, dilution 1:1,000), anti-RD4 (Millipore; mc, clone 1E1/A6, dilution 1:50), anti-alpha-internexin (Invitrogen; mc, clone 2E3, dilution 1:800), and anti-alpha-B-crystallin (Novocastra; mc, clone G2JF, dilution 1:100).

## Statistical Analysis

Missense mutation frequencies were compared between patients and controls using a Fisher exact test. Significance level was set at  $P < 0.05$ .

## Results

### Protein-Truncating Mutations

In the Belgian discovery cohort, we have reported four *TBK1* LoF mutations (Table 2) [Gijssels et al., 2015]. In this study, massive parallel exonic resequencing of the *TBK1* coding region was performed in the EU replication cohort of 1,755 patients, among which 1,271 FTD, 407 ALS patients, and 77 FTD-ALS, together with 1,109 European control individuals. In the patients, seven additional predicted LoF mutations were identified, including three small out-frame deletions, three nonsense mutations, and one splice donor-site mutation (Table 2). These mutations introduce a PTC and are expected to result in loss of transcript due to nonsense-mediated mRNA decay (NMD). No PTC or splice-site mutations were observed in the control subjects. We had already confirmed NMD for two PTC mutations, c.1192delT (p.Ser398Profs\*11) and c.1551\_1552insTT (p.Ser518Leufs\*32) [Gijssels et al., 2015]. In addition, for the predicted in-frame exon-skipping mutation c.992+1G>T (p.Gly272\_Thr331del) affecting exon 8, we demonstrated cryptic splicing activation and reduction of transcript and protein in brain [Gijssels et al., 2015]. In the present study, we demonstrated NMD for three more mutations. For c.288delT (p.Val97Phefs\*2), we showed a strong but incomplete reduction of the mutant transcript, for c.379C>T (p.Arg127\*) a complete absence of the mutant transcript (Fig. 1A and B). For the previously reported splice donor-site mutation in intron 11 (c.1340+1G>A), we confirmed out-of-frame skipping of exon 11 leading to a PTC (p.Ala417\*) (Fig. 1C) [Freischmidt et al., 2015]. For three of the mutation carriers in the EU replication cohort, c.288delT (p.Val97Phefs\*2), c.1340+1G>A (p.Ala417\*), and c.1385\_1388delCAGA (p.Thr462Lysfs\*3), we identified an additional affected relative with the mutation.

In addition to these proven loss-of-transcript mutations, we identified two novel predicted in-frame exon-skipping mutations. These splice donor-site mutations in intron 3 (c.228+1G>A) and intron 8 (c.992+4\_7delAGTA) are predicted to result in a deletion of 47 (p.Lys30\_Glu76del) and 60 amino acids (p.Gly272\_Thr331del). No cells or tissues from the carriers were available for transcript and protein analysis; therefore, we were unable to demonstrate the effect of these two mutations, and as a consequence, they were not considered further when calculating *TBK1* mutation frequencies.

### In-Frame Deletions

We have observed two in-frame, single amino acid deletions in the BE discovery cohort and one additional in-frame deletion in the EU replication cohort (Table 2). All three, c.235\_237delACA (p.Thr79del), c.499\_501delGAT (p.Asp167del), and c.1927\_1929delGAA (p.Glu643del), were absent from control subjects, and no other amino acid deletion mutations were observed in the control cohort. The p.Thr79del mutation was identified in a Spanish patient. The two other mutations, p.Asp167del and p.Glu643del, had been detected in Belgian patients [Gijssels et al., 2015]. The p.Glu643del mutation was present in one index patient and five affected relatives and an additional five unrelated index patients [Gijssels et al., 2015; Van Mossevelde et al., 2015]. In contrast to the protein-truncating mutations, the p.Glu643del mutation did not affect transcript levels but produced 50% loss of TBK1 protein in vivo [Gijssels et al., 2015]. In this study, we obtained comparable results for the Spanish mutation, p.Thr79del, with loss of expression only at the protein level observed in brain (Fig. 1D). The p.Asp167del behaved differently. Here, TBK1 protein expression in brain was preserved [Gijssels et al., 2015]. In vitro TBK1 protein expression of p.Thr79del and p.Glu643del mutations overexpressed in HEK293T cells was reduced but not completely absent (Supp. Fig. S1), whereas phospho-TBK1 was completely absent for p.Thr79del and p.Asp167del, and almost completely absent for p.Glu643del (Fig. 1E).

We further investigated the effect of the three in-frame deletions on NF $\kappa$ B activation, using an NF $\kappa$ B in vitro luciferase reporter assay. Results showed that all three amino acid deletion mutations severely disrupted NF $\kappa$ B activation (Fig. 2). The two single amino acid deletions located in the KD, p.Thr79del and p.Asp167del, resulted in a complete loss of NF $\kappa$ B activation. The p.Glu643del mutation that maps to the scaffold dimerization domain (SDD; residues 408–657) [Larabi et al., 2013], showed a highly significant reduction of about 70%.


Taken together, the in vivo protein expression and in vitro experiments demonstrated that, in addition to the protein-truncating LoF mutations, in-frame deletions also lead to TBK1 LoF through loss-of-protein and/or protein function.

In conclusion, in the European replication cohort, we identified seven LoF protein-truncating mutations and one LoF in-frame deletion mutation in a total of eight index patients, resulting in a mutation frequency of *TBK1* LoF mutations of 0.5% (8/1,755) overall and 0.2% in FTD patients (3/1,271), 0.5% in ALS patients (2/407), and 3.9% in FTD-ALS patients (3/77). Meta-analysis of the Belgian discovery cohort and the EU replication cohort resulted in a total mutation frequency for *TBK1* LoF mutations in the overall European study population of 0.7% (19/2,538), comprising 0.4% FTD patients (8/1,873), 1.3% ALS patients (7/554), and 3.6% FTD-ALS patients (4/111).

### TBK1 Missense Mutations

In the present study, we also investigated the prevalence and functional effect of missense mutations in the European study population. In the patient cohort, we identified 25 missense mutations in 26 patients, of which 16 were found only in patients (Table 3). In the control cohort, we identified 15 missense mutations in 16 individuals that were absent in patients (Table 3). We tested all 40 missense mutations using the NF $\kappa$ B reporter assay (Table 3; Fig. 2).

In the patient-only group, we found seven missense mutations in seven patients that showed an effect on NF $\kappa$ B induction (7/16 carriers, 44%). Six missense mutations showed a  $\geq 70\%$  decrease in



**Figure 2.** Impact of mutant *TBK1* on NFκB activity in the IFN pathway. Graphical representation of the mean NFκB-induced luciferase activity of identified in-frame amino acid deletions and missense mutations found in patients-only, shared by patients and controls, and in controls-only, normalized to the mean signal from wild type. Luciferase activities were measured in at least three independent experiments and measured five times per experiment. The different domains are indicated in different colors as shown in the figure legend. WT, wild type *TBK1* vector; Mock, empty vector containing no *TBK1*; S172A-KD, p.Ser172Ala *TBK1* kinase dead mutation. Mock and S172A-KD were used as negative controls. Error bars depict standard deviation and asterisks above the bars indicate significant difference from the wild-type level after Bonferroni correction ( $P < 0.001$ ). Protein numbering according to reference sequence NP\_037386.1.

NFκB activation as compared with wild-type *TBK1*, of which the c.281T>C (p.Leu94Ser) mutation showed a complete loss. These six missense mutations were located in the KD of *TBK1*. To a lesser extent but still significant, the c.1252A>G (p.Ile418Val) mutant in the SDD decreased NFκB induction by 45%.

In the group of missense mutations present in both patients and controls, just one missense mutation c.871A>G (p.Lys291Glu), also located in the KD domain and present in one patient and two control subjects, showed a significant decrease in NFκB induction (3/25 carriers, 12%).

Of the 15 missense mutations that were observed in control subjects only, two mutations located in the KD protein domain showed a significant reduction, with a complete loss for c.47G>A (p.Gly16Asp) and a ~25% reduction for c.428G>A (p.Arg143His) (2/16 carriers, 13%).

When comparing the prevalence of missense mutations with a compromised NFκB activation capacity (= functional missense mutations) in patients and controls, we observed about twice as many in patients. In the patients, eight carriers of a functional and therefore potentially pathogenic missense mutation were identified (8/2,538, 0.32%) as compared to four in control subjects (4/2,183, 0.18%) ( $P = 0.40$ ). Although functional missense mutations were identified in the patient-only, the patient and control, as well as the control-only group, over three times as many carriers of functional missense mutations were counted in the patient-only group (7/16, 44%) versus the group of carriers of missense mutations that were also observed in the control population (5/41, 12%) ( $P = 0.025$ ).

### Phenotypic Characteristics of *TBK1* Mutation Carriers

Demographic, genetic, and clinical features of the pathogenic and possibly pathogenic *TBK1* mutation carriers (protein-truncating mutations, in-frame deletions, and functional missense mutations) are summarized in Table 4.

Eleven of the 19 index patients with a *TBK1* LoF mutation had FTD as presenting clinical phenotype. In this subset of patients, nine developed FTD without clinical signs of MND. In the years following first diagnosis, two patients developed ALS and another patient progressed into a corticobasal syndrome (CBS). Eight patients presented first with ALS, of which one showed concomitant cognitive deterioration suffering from a severe memory disorder and visuo-constructional deficits but no specification of the dementia diagnosis was possible. Of all patients diagnosed with ALS ( $n = 10$ ), four had bulbar onset and one had spinal onset. In five ALS patients, the site of onset was not specified. Of all FTD (or unspecified dementia) patients ( $n = 12$ ), the majority was diagnosed with bvFTD (8/12). Three others presented with a language variant of FTD, progressive nonfluent aphasia (PNFA) or PPA. The remaining patient received a diagnosis of unspecified dementia (together with ALS). Mean age at onset in all 19 *TBK1* LoF carriers was  $63.9 \pm 7.8$  years (range 48–78). Of the 12 patients that died, mean age at death was  $65.5 \pm 8.9$  years (range 50–77) with an average disease duration of  $42 \pm 40$  months (range 6–136).

Neuropathological examination was performed in three of the deceased patients. The patient with the p.Val97Phefs\*2 mutation displayed pure MND with TDP-43 inclusions. The carrier of the p.Ala417\* mutation showed mild TDP-43 proteinopathy in affected brain regions (type B). Neuropathological investigation in the p.Thr79del carrier confirmed the diagnosis of FTLD-MND-TDP (type B), but additional argyrophilic grain disease stage III was noted (Fig. 3).

In the eight functional missense mutation carriers, four presented first with FTD, of whom one developed concomitant ALS, and four presented with ALS only. Again, in the FTD patients, bvFTD was the predominant subtype (3/4). In the ALS patients, two had spinal onset and two had bulbar onset. Average onset age was low at  $46.6 \pm 7.4$  years (range 34–57). The three patients that passed away died at relatively young ages of 43, 59, and 61 years (average age at death  $54.3 \pm 9.9$  years).

**Table 3. *TBK1* Missense Mutations in the European Study Population**

cDNA	Predicted protein	Domain	dbSNP	NFκB activity	FTD <i>n</i> = 1,873	FTD-ALS <i>n</i> = 111	ALS <i>n</i> = 554	Controls <i>n</i> = 2,183
Missense mutations found in patients only								
c.188A>G	p.Asn63Ser	KD	-	n.s.	1			
c.281T>C	p.Leu94Ser	KD	-	Reduced			1	
c.362G>A	p.Gly121Asp	KD	-	Reduced			1	
c.427C>T	p.Arg143Cys	KD	-	Reduced	1			
c.687G>T	p.Arg229Ser	KD	-	Reduced			1	
c.731G>T	p.Gly244Val	KD	-	Reduced		1		
c.737T>C	p.Ile246Thr	KD	-	Reduced			1	
c.794T>C	p.Val265Ala	KD	-	n.s.	1			
c.812G>T	p.Arg271Leu	KD	-	n.s.	1 <sup>a</sup>			
c.1057A>G	p.Ile353Val	ULD	-	n.s.	1			
c.1190T>C	p.Ile397Thr	linker	-	n.s.			1	
c.1217A>G	p.Tyr406Cys	linker	-	n.s.	1			
c.1252A>G	p.Ile418Val	SDD	rs138839127	Reduced	1			
c.1544T>C	p.Ile515Thr	SDD	rs151225287	n.s.			1 <sup>a</sup>	
c.1612C>T	p.His538Tyr	SDD	-	n.s.		1		
c.1717C>G	p.Arg573Gly	SDD	-	n.s.	1			
Missense mutations found in patients and control subjects								
c.217A>G	p.Ile73Val	KD	-	Increased	2			1
c.550A>G	p.Met184Val	KD	-	n.s.	1			1
c.871A>G	p.Lys291Glu	KD	rs34774243	Reduced	1 <sup>a</sup>			2
c.964C>T	p.His322Tyr	ULD	rs145905497	n.s.			1 <sup>a</sup>	1
c.1179A>G	p.Ile393Met	linker	-	n.s.	1			1
c.1603G>A	p.Ala535Thr	SDD	rs199905735	n.s.	1 <sup>a</sup>			1
c.1709A>G	p.Lys570Arg	SDD	-	n.s.	1			2
c.1792A>G	p.Met598Val	SDD	-	n.s.	1			2
c.1957G>C	p.Glu653Gln	SDD	rs144370662	n.s.		1		4
Missense mutations found in control subjects only								
c.40A>G	p.Ile14Val	KD	-	n.s.				1
c.47G>A	p.Gly16Asp	KD	-	Reduced				1
c.149A>C	p.Asp50Ala	KD	-	Increased				1
c.167T>C	p.Phe56Ser	KD	-	n.s.				1
c.428G>A	p.Arg143His	KD	-	Reduced				1
c.944C>T	p.Ser315Leu	ULD	rs369620088	n.s.				1
c.1037T>C	p.Ile346Thr	ULD	-	n.s.				1
c.1040C>T	p.Ser347Phe	ULD	-	n.s.				1
c.1150C>T	p.Arg384Trp	ULD	-	n.s.				1
c.1364A>G	p.Asn455Ser	SDD	-	Increased				1
c.1366G>C	p.Glu456Gln	SDD	-	n.s.				1
c.1538G>A	p.Gly513Glu	SDD	-	n.s.				1
c.1796C>T	p.Thr599Met	SDD	-	n.s.				1
c.1952C>T	p.Thr651Ile	SDD	-	n.s.				1
c.2170C>T	p.Arg724Cys	CTD	rs185524052	n.s.				2

*TBK1* functional domains according to Larabi et al. (2013): KD, kinase domain (residues 1–307); ULD, ubiquitin-like domain (residues 309–384); linker, linker (residues 385–407); SDD, scaffold dimerization domain (residues 408–657); CTD, C-terminal domain (residues 657–745). Results of the in vitro NFκB luciferase reporter assay measuring the effect of mutant *TBK1* on NFκB activity are listed (see also Fig. 2). Reduced indicates that a significant reduction in luciferase activity was measured; increased indicates that a significant increase in luciferase activity was measured. n.s., no significant change in luciferase activity was measured.

<sup>a</sup>Refers to mutations and carriers identified in the Belgian discovery cohort that were published earlier [Gijssels et al., 2015]. cDNA numbering according to reference sequence NM\_013254.3. Nucleotide positions refer to cDNA sequence and nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. Protein numbering was according to the reference sequence NP\_037386.1.

### Neuropathology of the p.Thr79del Mutation Carrier

Macroscopic evaluation showed a moderate and temporally accentuated brain atrophy with an unfixed brain weight of 1,340 g. On histological examination (Fig. 3), neuronal loss, reactive astrogliosis, and microglial activation were observed predominantly involving the medial temporal lobe. Abundant and widespread neuronal TDP-43 protein inclusions were detected in neurons of the limbic system including amygdala, entorhinal, and transentorhinal region, hippocampus (dentate gyrus and CA1 sector), cingulate cortex, inferior temporal cortex, and in the motor cortex, with only few inclusions in frontal and parietal cortex, in basal ganglia and thalamus, and brainstem nuclei. Type of inclusions varied and comprised compact and ring-like neuronal cytoplasmic inclusions that were observed predominantly, but not exclusively, in superficial cortical layers and also

throughout the cortex. Only very isolated dystrophic neurites were detected. Diffuse granular cytoplasmic immunoreactivity (neuronal "preinclusions") was frequently seen in middle-sized neurons of frontal and temporal cortex, limbic system, basal ganglia, brainstem, and spinal cord. Skein-like inclusions were evident in motor neurons of the anterior horn of the spinal cord, but also in motor neurons of the hypoglossal nucleus, pigmented neurons of the substantia nigra, and few striatal neurons. Frequent oligodendroglial inclusions were detected both in white matter and gray matter (arrows). Involvement of upper motor neurons was appreciated, and there was florid corticospinal tract degeneration showing myelin and axonal loss, and abundant CD68-positive macrophages, whereas lower motor neurons of anterior horns of spinal cord were moderately affected. The distribution pattern of pathology was most concordant with FTLD type B according to the current FTLD consensus classification



**Table 4. Clinical and Pathological Phenotype of Patients Carrying a *TBK1* LoF Mutation or Possibly Pathogenic Missense Mutation**

Mutation	Origin	Gender	Clinical diagnosis <sup>a</sup>	Subtype <sup>b</sup>	Family history	Age at onset (years)	Age at last examination/death (years)	Disease duration (months)	Additional information
<b>Truncating mutations</b>									
p.Gln*2 <sup>c</sup>	Spanish	Female	FTD	bvFTD		56	60	>53	
p.Lys29Argfs*15	German	Male	FTD	PNFA + PSP		73	†77	48	
p.Val97Phefs*2	Swedish	Male	ALS		+	62	†63		MND-TDP
p.Arg117*	Italian	Male	FTD	bvFTD	+	67	†74	86	
p.Arg127*	German	Female	ALS	Bulbar		70	Alive		
p.Trp445*	Spanish	Female	FTD + CBS	PNFA/agrammatic variant		78	84	>72	
p.Gly272..Thr331del <sup>c</sup>	Belgian	Male	FTD	bvFTD	+	48	†50	29	
p.Ser398Profs*11 <sup>c</sup>	Belgian	Male	ALS	Bulbar	+	59	Alive	>75	
p.Ala417*	Swedish	Female	FTD	bvFTD	+	68	†71	27	FTLD-TDP type B
p.Thr462Lysfs*3	German	Male	ALS + D		+	74	†75	11	LMN>>UMN
p.Ser518Leufs*32 <sup>c</sup>	Belgian	Female	ALS		+	64	†64	6	
<b>In-frame deletions</b>									
p.Thr79del	Spanish	Male	FTD + ALS	bvFTD + bulbar		56	†58	18	FTLD-MND-TDP type B + argyrophilic grain disease (stage III)
p.Asp167del <sup>c</sup>	Belgian	Male	ALS			60	†61		
p.Glu643del <sup>c</sup>	Belgian	Female	FTD + ALS	bvFTD + spinal	+	62	†74	136	
p.Glu643del <sup>c</sup>	Belgian	Female	FTD	bvFTD	+	64	Alive	>109	
p.Glu643del <sup>c</sup>	Belgian	Male	ALS	Bulbar	+	51	†53	20	
p.Glu643del <sup>c</sup>	Belgian	Male	ALS			63	†66		
p.Glu643del <sup>c</sup>	Belgian	Male	FTD	PPA	+	70	†73	42	
p.Glu643del <sup>c</sup>	Belgian	Female	FTD	bvFTD		69	Alive	>99	
<b>Functional missense mutations</b>									
p.Leu94Ser	Bulgarian	Male	ALS	Spinal	+	44	55	>120	Slow disease progression
p.Gly121Aspc	Spanish	Male	ALS	Spinal		34	39	>60	Slow disease progression
p.Arg143Cys	German	Male	FTD	bvFTD		45			
p.Arg229Ser	German	Male	ALS			47			
p.Gly244Val	Portuguese	Female	FTD + ALS	Bulbar	+	41	†43		C9orf72 repeat expansion carrier
p.Ile246Thr	German	Female	ALS	Bulbar		57	†59		
p.Lys291Glu <sup>c</sup>	Belgian	Male	FTD	bvFTD	+	52	†61		
p.Ile418Val	Portuguese	Female	FTD	bvFTD	+	53	54		

<sup>a</sup>Presenting diagnosis or symptoms are listed first.

<sup>b</sup>Clinical subtype is given where documented. In FTD, the subtypes behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), progressive nonfluent aphasia (PNFA), semantic dementia (SD), and progressive supranuclear palsy (PSP) are specified where documented. In ALS, spinal or bulbar onset is specified where documented.

<sup>c</sup>Refers to mutation carriers identified in the Belgian discovery cohort that were published earlier [Gijssels et al., 2015; Van Mossevelde et al., 2015].

CBS, corticobasal syndrome; MND, motor neuron disease; LMN, lower motor neuron symptoms; UMN, upper motor neuron symptoms; D, unspecified dementia. +, a positive family history was documented.


[Mackenzie et al., 2011]. In addition, concomitant argyrophilic grain pathology (AgD) was observed. This was characterized by the presence of hyperphosphorylated tau (AT8) and four-repeat tau-positive grains in amygdala, entorhinal and transentorhinal cortex, CA1 sector of the hippocampus, and cingulum, along with frequent pre-tangles and neuropil threads, tau-positive oligodendroglial coiled bodies in medial temporal white matter, bush-like astrocytes, and ballooned neurons in amygdala corresponding to stage III according to Saito et al. (2004).

## Discussion

In the pursuit of the missing heritability of the FTD-ALS spectrum, *TBK1* haploinsufficiency was recently put forward as a novel disease mechanism. Classical LoF mutations include nonsense and frameshift mutations that lead to mutant transcripts containing a PTC, which are degraded by NMD resulting in a 50% loss of protein.

In addition to loss of transcript, several other possibilities can lead to loss-of-protein or protein function. For example, deletions of one or more key amino acids due to small in-frame indels or in-frame exon skipping and missense mutations can affect the catalytic function or the stability of the protein. In the present study, we investigated the full mutation spectrum of *TBK1* and its associated phenotypic spectrum in a large study population of 2,538 European FTD and ALS patients. In addition to protein-truncating LoF mutations, the functional effect of in-frame amino acid deletions and missense mutations was further explored in vivo on protein level and in vitro by an NFκB-induced luciferase reporter assay as functional readout for TBK1 activity.

In total, we identified 11 index patients carrying a *TBK1* protein-truncating mutation (Table 2). Nine mutations were nonsense or frameshift mutations, of which five, (c.86delA (p.Lys29Argfs\*15), p.Val97Phefs\*2, p.Arg127\*, c.1335G>A (p.Trp445\*), p.Thr462Lysfs\*3), are reported here for the first time. Multiple studies have demonstrated that PTC mutations in *TBK1*



**Figure 3.** Neuropathology features of the FTD-ALS patient with the *TBK1* p.Thr79del mutation. Severe neuronal loss, gliosis, and loosening of the neuropil are observed in entorhinal and transentorhinal region (lower image) as compared with relatively well-preserved frontal cortex (upper image) (HE) (A). Abundant TDP-43 protein aggregates in neurons and oligodendroglial cells (B), better seen in (C) at higher magnification (arrows). Hippocampal dentate gyrus shows some granular neurons lacking physiological nuclear immunoreactivity but shifting toward pathological inclusions in the cytoplasm (D). Morphological spectrum of neuronal cytoplasmic inclusions (E–J), seen as compact bodies (E), diffuse granular cytoplasmic immunoreactivity or “preinclusion” type (F), skein-like inclusions (G, inset), compact ring-like inclusions (H), or a combination of diffuse cytoplasmic and compact in the same motor neuron (I). Signs of corticospinal tract degeneration at the level of the spinal cord with marked reduction of axonal density as shown by antineurofilament immunohistochemistry (K, inset shows regular density of axons for comparison), and increased macrophagic activity (L, anti-CD68 immunohistochemistry, inset shows regular density of CD68+ cells in the spinal cord for comparison). Neuropathological features of concomitant argyrophilic grain pathology (M–P). Ballooned cells are seen in amygdala (M) and are nicely stained by hyperphosphorylated tau (AT8, inset). Moreover, frequent hpTau-positive grains, mainly composed of four-repeat tau isoforms, are detected in the limbic system (N, CA1 sector is shown), and represent enlargements/verruccosities of dendritic spines (N, inset). Oligodendroglial coiled bodies (O) and bush-like astrocytes (P) accompany the full picture.

lead to loss or severe reduction of mutant transcript levels by NMD [Freischmidt et al., 2015; Gijssels et al., 2015; Pottier et al., 2015], which we additionally confirmed in the present study (Fig. 1A and B). Further, we detected two splice donor-site mutations. The c.1340+1G>A in intron 11 leads to out-frame skipping of exon 11 and the introduction of a PTC (p.Ala417\*). Exon 11 skipping by this mutation was previously demonstrated by Freischmidt et al. (2015) and was identified in five Swedish individuals: three sporadic ALS patients, one familial ALS patient, and one unaffected individual with a family history of ALS. Interestingly, the FTD patient in whom we identified the same p.Ala417\* mutation was also of Swedish origin, potentially indicative of a founder mutation. In a Belgian FTD patient, we identified the c.992+1G>T mutation in the consensus

splice donor sequence of intron 8 and demonstrated activation of a cryptic splice-site upstream in exon 8, resulting in a frameshift and 30%–50% reduced expression in blood and brain [Gijssels et al., 2015]. In addition to these 11 proven protein-truncating mutations, we detected two additional splice donor-site mutations in intron 3 (c.228+1G>A) and intron 8 (c.992+4.7delAGTA) (Table 2). Both are predicted to lead to in-frame skipping of their respective exons. Unfortunately, no biomaterials of the carriers were available to investigate potential cryptic splicing or the formation of unstable/nonfunctional protein due to the loss of conserved amino acid sequence; therefore, their pathogenic effect remains speculative.

In addition to *TBK1* protein-truncating mutations, we identified eight carriers of three in-frame amino acid deletions: p.Thr79del,

p.Asp167del, and p.Glu643del (Table 2). For p.Thr79del and p.Glu643del, we demonstrated a near total loss of mutant protein in vivo and partial loss in vitro, likely due to protein instability [Gijssels et al., 2015] (Fig. 1D; Supp. Fig. S1). In contrast, this was not the case for p.Asp167del for which TBK1 protein expression was preserved [Gijssels et al., 2015] (Supp. Fig. S1). Yet, total (p.Thr79del and p.Asp167del) or highly reduced (p.Glu643del) loss of TBK1 autophosphorylation and NF $\kappa$ B activation was measured for all three mutations. Therefore, the observed effects of p.Thr79del and p.Glu643del on autophosphorylation and on NF $\kappa$ B activation might also result from reduced activity of the remaining mutant protein, in addition to reduced protein expression. The deleterious effect of p.Asp167del was to be expected since Asp167 is located in the activation loop of the KD, of which phosphorylation is required for TBK1 activation [Larabi et al., 2013]. Also, p.Thr79del and p.Glu643del affect highly conserved amino acids and map to the catalytic KD and the SDD, located further downstream. TBK1 is a multifunctional kinase, phosphorylating a wide range of substrates, including the NF $\kappa$ B complex. Importantly, as indicated above, TBK1 itself is activated by homodimerization and subsequent autophosphorylation. Although it is currently not known which function(s) of TBK1 contribute to the disease mechanism(s) in FTD and ALS, measuring NF $\kappa$ B induction by observed TBK1 mutations compared with wild-type TBK1 can serve as a first functional readout for their effect on TBK1 function related to the NF $\kappa$ B pathway, awaiting more tailored functional pathogenicity assays. In vivo, the two mechanisms of LoF through loss-of-protein and protein function may very well complement each other.

The largest group of mutations that we identified were missense mutations. In total, screening of 2,538 patients and 2,183 control individuals revealed 40 missense mutations, spread over the different protein domains and observed both in patients and controls (Table 3; Fig. 2). Using the NF $\kappa$ B reporter assay, we were able to discriminate 10 functional missense mutations that abolished or significantly reduced NF $\kappa$ B activation. Functional missense mutations mainly clustered in the KD, with only one exception for the p.Ile418Val mutation located in the SDD, and most likely exert their effect through a defect in the catalytic kinase activity of TBK1. These functional missense mutations are possibly pathogenic, although their degree of pathogenicity may be variable, correlating with a complete absence of TBK1 activity for some to a significant reduction of ~50%, or more for others (Fig. 2). The p.Leu94Ser mutation was a bit particular compared to the other functional missense mutations as it showed reduced protein expression, probably due to unstable protein (Supp. Fig. S1). The loss of NF $\kappa$ B activation by this mutation might therefore result from a combination of both loss-of-protein and protein function, similar to what was observed for some in-frame single amino acid deletions. For three missense mutations, one patient-specific c.217A>G (p.Ile73Val) and two control-specific c.149A>C (p.Asp50Ala) and c.1364A>G (p.Asn455Ser), the NF $\kappa$ B reporter assay measured a significant increase in activity (Table 3; Fig. 2). The biological relevance of these observations is not clear; however, an increase in TBK1 activity does not seem relevant in the context of a LoF disease mechanism, and most likely these missense mutations are neutral with respect to ALS and FTD.

Even though occasional functional missense mutations were observed in the healthy study population (4/2,183, 0.18%), twice as many were present in patients (8/2,538, 0.32%). In other words, of the 12 carriers of a functional missense mutation, eight (67%) were diagnosed with ALS or FTD. When we looked specifically at missense mutations that were only observed in patients, 44% (7/16) had a compromised NF $\kappa$ B activation capacity compared with 12% (5/41) of the missense mutations observed in controls, which was

statistically significant ( $P = 0.025$ ). The observed enrichment of functional TBK1 missense mutations in patients suggests that they may function as high-risk alleles through various degrees of loss-of-protein function.

Mutations in the KD affect the catalytic domain and likely affect phosphorylation of all targets. As such, the NF $\kappa$ B activation assay may be considered a valid test of pathogenicity because it measures the kinase activity, independent of substrate. However, we cannot exclude that additional missense mutations with no assessable effect on the NF $\kappa$ B/IFN pathway may be pathogenic. Other pathways may be affected by hampered binding or phosphorylation of the respective substrates. Indeed, for at least one additional missense mutation, c.1717C>G (p.Arg573Gly) located in the SDD, we have evidence for cosegregation in four affected sibs, suggestive of an autosomal-dominant inheritance. This sib-ship presented with a heterogeneous disease presentation of FTD, AD-type dementia, and MND (Gómez-Tortosa, Submitted). Mutations in other domains, such as the C-terminal substrate-binding domain, may selectively affect specific kinase activities, and therefore the NF $\kappa$ B assay may not be a good readout for pathogenicity for these mutations, depending on which TBK1 functions are central to disease. As proposed by Freischmidt (2015), loss of OPTN binding may be sufficient to cause ALS and FTD [Freischmidt et al., 2015]. To further investigate the possibility that some of the observed missense mutations had an effect on OPTN binding, we modeled the missense mutations of the patient and control fraction outside the KD by OPTN coimmunoprecipitation. The missense mutations under study did not show any evidence for reduced OPTN binding (data not shown). Since TBK1 operates as a homodimer, pathogenic TBK1 missense mutations, regardless of which domain they are located in, may in addition also have a dominant-negative effect by competing with wild-type TBK1.

Mean onset age in the 19 TBK1 LoF mutation carriers (protein-truncating mutations + in-frame deletions) was  $63.9 \pm 7.8$  years (range 48–78). Remarkable in terms of survival was the huge range in disease duration from 6 to 136 months. In terms of phenotypic heterogeneity, one patient (p.Lys29Argfs\*15) showed a clinically mixed picture of behavioral disturbances (bvFTD), PNFA, and symmetric Parkinsonian syndrome of bilateral rigidity, hypokinesia, vertical gaze paresis, and gait disorder, suggestive for progressive supranuclear palsy. Patient (p.Trp445\*) was diagnosed with CBS and nonfluent/agrammatic variant PNFA. Neuropathological examination of the FTLD-ALS patient with the p.Thr79del mutation showed a temporal accentuated brain atrophy with abundant neuronal and glial TDP-43 protein aggregates, with upper and lower motor neuron involvement, and AgD in the medial temporal lobe. The concomitant AgD probably contributed to the lobar atrophy and to the clinical picture of this patient. AgD has clinically been related to mild forms of dementia with mood and behavioral disturbances, personality changes, aggressiveness, and even psychosis. AgD pathology is considered to occur more frequently in aged than in younger individuals [Pham et al., 2011], and has also been detected in cognitively normal subjects. Moreover, AgD has been described in association with several other neurodegenerative conditions. Coincidental TDP-43 protein aggregates in the medial temporal lobe have been repeatedly reported to occur relatively frequently in association with AgD [Fujishiro et al., 2009; Arnold et al., 2013]. Therefore, the co-occurrence of FTLD-TDP and AgD in this relatively young (age at death 58 years) patient may suggest some—sporadic or mutation-driven—link between abnormal Tau and TDP-43 protein deposition.

The absence of a documented family history in 42% (8/19) of the LoF mutation carriers underscores the marked reduced



clinical penetrance of *TBK1* mutations. This reduces penetrance, which has also been confirmed in multigenerational families segregating a *TBK1* LoF mutation [Freischmidt et al., 2015; Gijssels et al., 2015; Van Mossevelde et al., 2015], explains why apparently sporadic patients carry a Mendelian *TBK1* mutation. In these patients, family history may be obscured due to small family size or pleiotropic manifestation of *TBK1* mutations as FTD or ALS. Inquiry of family history in isolated FTD patients may not take into account relatives with motor neuron symptoms and, vice versa, in ALS patient's relatives with cognitive problems. Reduced penetrance and observation of Mendelian mutations in apparently sporadic patients or isolated patients is also a recurring theme in other major Mendelian genes in FTD and ALS, such as *GRN* (MIM# 138945) and *C9orf72*. We previously showed that 50% of *TBK1* carriers are affected by the age of 70 [Van Mossevelde et al., 2015]. In the extended set of 19 *TBK1* LoF carriers from this study, just one patient was affected by the age of 50 (5%), six by the age of 60 (32%), and 16 by the age of 70 years (84%). It is noteworthy that in the carriers of a functional missense high-risk variant, average onset age of  $46.6 \pm 7.4$  years (range 34–57) was markedly lower than in the group of LoF mutations. Two of the *TBK1* missense variant carriers also carried a *C9orf72* repeat expansion. Interestingly, the patient with the *TBK1* c.731G>T (p.Gly244Val) mutation shown to attenuate NF $\kappa$ B induction in combination with a *C9orf72* repeat expansion had a pronounced early disease onset of 41 years. We already described this patient when we identified the *C9orf72* repeat expansion in FTD-ALS spectrum patients [van der Zee et al., 2013]. Her disease course was characterized by rapidly progressive FTD with bulbar ALS and death after 2 years [Chester et al., 2013]. In contrast, the other *C9orf72* expansion carrier with the *TBK1* c.550A>G (p.Met184Val) mutation without effect on the NF $\kappa$ B activation had an onset age of 70 years. Considering the high prevalence of *C9orf72* repeat expansions in FTD-ALS spectrum patients, it is not surprising that in some patients a mutation in *TBK1*, *GRN*, or another gene can co-occur with a *C9orf72* repeat expansion that may influence disease penetrance.

In conclusion, we investigated a large European study population of 2,538 European FTD-ALS spectrum patients to get a deeper appreciation of the mutation frequency, mutation spectrum, and the genotype–phenotype profile of *TBK1* patient carriers. In addition to the typical LoF protein-truncating mutations, we demonstrated that in-frame amino acid deletion mutations and a significant fraction of the missense mutations, particularly those mapping to the kinase domain, also lead to loss-of-protein and/or protein function. We observed a mutation frequency for *TBK1* LoF protein-truncating and in-frame deletion mutations of 0.7%, representing 0.4% in the FTD, 1.3% in the ALS, and 3.6% in the FTD-ALS clinical subgroups. Taking also the functional missense high-risk alleles into account, mutation frequencies increased to 1.1% overall and 0.6% in FTD, 2.0% in ALS, and 4.5% in FTD-ALS patients. These mutation frequencies are relatively low compared with other FTD-ALS spectrum genes like *C9orf72*. Nevertheless, the higher mutation frequencies in FTD-ALS and in ALS patients warrant diagnostic testing. Furthermore, as indicated above, calculated *TBK1* mutation frequencies may still be an underestimation with a substantial fraction of missense mutations remaining unresolved. Although *TBK1* is a well-characterized, multifunctional kinase, which of the *TBK1* functions that specifically contribute to the disease mechanism in FTD and ALS are poorly understood. Hopefully, in the years to come, more functional data will become available, and based on this information, better informed and targeted pathogenicity assays or biomarkers can be developed for more reliable risk prediction and counseling in *TBK1* mutation carriers.

## Belgian Neurology (BELNEU) consortium side author list

The following members of the BELNEU consortium contributed to the clinical and pathological phenotyping and follow-up of the Belgian patient cohorts: Johan Goeman and Dirk Nuytten (Hospital Network Antwerp, Antwerp); Katrien Smets (Antwerp University Hospital, Edegem); Wim Robberecht and Philip Van Damme (University Hospitals Leuven Gasthuisberg, Leuven); Jan De Bleecker, Patrick Santens, and Bart Dermaut (University Hospital Ghent, Ghent); Jan Versijpt and Alex Michotte (University Hospital Brussels, Brussels); Adrian Ivanoiu (Saint-Luc University Hospital, Brussels); Olivier Deryck and Bruno Bergmans (General Hospital Sint-Jan Brugge, Bruges); Jean Delbeck (General Hospital Sint-Maria, Halle); Marc Bruylant (General Hospital Gloreux Ronse); Christiana Willems (Jessa Hospital, Hasselt); and Eric Salmon (University of Liège and Memory Clinic, CHU Liège, Liège).

## European Early-Onset Dementia (EU EOD) consortium side author list

The following members of the EU EOD consortium contributed to the clinical and pathological phenotyping and follow-up of the patients at their site that were included in the EU EOD cohort: Pau Pastor (University Hospital Mútua de Terrassa and Fundació Docència i Recerca Mútua Terrassa, University of Barcelona School of Medicine, Terrassa, Barcelona, Spain); Pau Pastor and Sara Ortega-Cubero (CIBERNED Instituto de Salud Carlos III, Madrid, Spain); Sara Ortega-Cubero (Department of Neurology, Complejo Asistencial Universitario de Palencia, Palencia, Spain); Luisa Benussi and Roberta Ghidoni (Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy); Giuliano Binetti (MAC Memory Center and Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy); Isabel Hernández, Mercè Boada, and Agustín Ruiz (Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain); Sandro Sorbi, Benedetta Nacmias, and Silvia Bagnoli (Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy); Sandro Sorbi (IRCCS Don Carlo Gnocchi Scandicci, Florence, Italy); Raquel Sanchez-Valle and Albert Llado (Hospital Clínic, IDIBAPS, Barcelona, Spain); Isabel Santana and Maria Rosário Almeida (University of Coimbra, Coimbra, Portugal); Giovanni B Frisoni (Hôpitaux Universitaires de Genève et Université de Genève, Genève, Switzerland and IRCCS Fatebenefratelli, Brescia, Italy); Walter Maetzler (Hertie Institute for Clinical Brain Research, Tübingen, Germany); Radoslaw Matej (Thomayer Hospital, Prague and Charles University, Prague, Czech Republic); Matthew J. Fradakis (NeuroRARE Centre for Rare and Genetic Neurological & Neuromuscular Diseases & Neurogenetics Athens, Greece); Gabor G. Kovacs (Medical University of Vienna, Vienna, Austria); and Gian Maria Fabrizi and Silvia Testi (University of Verona, Verona, Italy).

## Acknowledgments

The authors thank the personnel of the Neuromics Support Facility of the VIB Center for Molecular Neurology (<http://www.vibgeneticservicefacility.be>) and the Antwerp Biobank of the Institute Born-Bunge for their expert support. The Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS thanks all brain donors and families for generous brain donation for research and the Neurological Tissue Bank of the IDIBAPS Biobank for data and sample procurement. Caroline Graff wishes to express



her acknowledgements to Inger Nennesmo (for the neuropathological assessments), Huei-Hsin Chiang, Jenny Björkström, Lena Lilius, Charlotte Forsell, Marie Fallström (Department of Neurobiology, Care Sciences and Society [NVS], Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet and Department of Geriatric Medicine, Genetics Unit, Karolinska University Hospital, Stockholm, Sweden), and The Brain Bank at Karolinska Institutet. The LMU Munich site acknowledges the essential support of the team at Zentrum für Neuropathologie und Prionforschung, Ludwig-Maximilians-Universität Munich (Thomas Arzberger, Sigrun Roeber, Manuela Neumann, Armin Giese, and Hans Kretzschmar) for their neuropathological work and the safekeeping of DNA samples.

**Disclosure statement:** The authors declare no conflict of interest.

## References

- Arnold SJ, Dugger BN, Beach TG. 2013. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. *Acta Neuropathol* 126:51–57.
- Le Ber I, De Septenville A, Millicamps S, Camuzat A, Caroppo P, Couratier P, Blanc F, Lacomblez L, Sellal F, Fleury M-C, Meininger V, Cazeneuve C, et al. 2015. TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. *Neurobiol Aging* 36:3116.e5–3116.e8.
- Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, Papetti A, Stuari C, Di Luca M, Gennarelli M, Padovani A. 2009. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. *Hum Mutat* 30:E974–E983.
- Brooks BR, Miller RG, Swash M, Munsat TL. 2000. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 1:293–299.
- Chester C, de Carvalho M, Miltenberger G, Pereira S, Dillen L, van der Zee J, Van Broeckhoven C, de Mendonça A. 2013. Rapidly progressive frontotemporal dementia and bulbar amyotrophic lateral sclerosis in Portuguese patients with C9orf72 mutation. *Amyotroph Lateral Scler Frontotemporal Degener* 14:70–72.
- Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion A, Leblond CS, Couthouis J, Lu Y, Wang Q, Brian J, Ren Z, Keebler J, et al. 2015. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. *Science* 347:1436–1441.
- Clément J-F, Meloche S, Servant MJ. 2008. The IKK-related kinases: from innate immunity to oncogenesis. *Cell Res* 18:889–899.
- Cruts M, Theuns J, Van Broeckhoven C. 2012. Locus-specific mutation databases for neurodegenerative brain diseases. *Hum Mutat* 33:1340–1344.
- Cruts M, Gijselink I, Van Langenhove T, van der Zee J, Van Broeckhoven C. 2013. Current insights into the C9orf72 repeat expansion diseases of the FTL/ALS spectrum. *Trends Neurosci* 36:450–459.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, et al. 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72:245–256.
- Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Müller K, Marroquin N, Nordin F, Hübers A, Weydt P, Pinto S, Press R, et al. 2015. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. *Nat Neurosci* 18:631–636.
- Fujishiro H, Uchikado H, Arai T, Hasegawa M, Akiyama H, Yokota O, Tsuchiya K, Togo T, Iseki E, Hirayasu Y. 2009. Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. *Acta Neuropathol* 117:151–158.
- Gelpi E, van der Zee J, Turon Estrada A, Van Broeckhoven C, Sanchez-Valle R. 2014. TARDBP mutation p.Ile383Val associated with semantic dementia and complex proteinopathy. *Neuropathol Appl Neurobiol* 40:225–230.
- Gijselink I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, Janssens J, Bettens K, Van Cauwenbergh C, Pereson S, Engelborghs S, Sieben A, et al. 2012. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. *Lancet Neurol* 11:54–65.
- Gijselink I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B, Engelborghs S, Vandenbulcke M, De Baets G, Bäumer V, Cuij I, Van den Broeck M, et al. 2015. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. *Neurology* 85:2116–2125.
- Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, et al. 2011. Classification of primary progressive aphasia and its variants. *Neurology* 76:1–10.
- Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wu J, Ding J, McCluskey L, et al. 2010. Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron* 68:857–864.
- Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard J-P, Lacomblez L, Pochigaeva K, Salachas F, Pradat P-F, Camu W, et al. 2008. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet* 40:572–574.
- Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vandenberg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, et al. 2009. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* 323:1205–1208.
- Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenbergh R, Gijssels I, Van den Broeck M, Mattheijssens M, Peeters K, De Deyn PP, Cruts M, Van Broeckhoven C. 2010. Genetic contribution of FUS to frontotemporal lobar degeneration. *Neurology* 74:366–371.
- Larabi A, Devos JM, Ng S-L, Nanao MH, Round A, Maniatis T, Panne D. 2013. Crystal structure and mechanism of activation of TANK-binding kinase 1. *Cell Rep* 3:734–746.
- Lomen-Hoerth C, Anderson T, Miller B. 2002. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. *Neurology* 59:1077–1079.
- Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DMA, Lee VMY. 2011. A harmonized classification system for FTLD-TDP pathology. *Acta Neuropathol* 122:111–113.
- Van Mossevelde S, van der Zee J, Gijssels I, Engelborghs S, Sieben A, Van Langenhove T, De Bleecker J, Baets J, Vandenbulcke M, Van Laere K, Ceysens S, Van den Broeck M, et al. 2015. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. *Brain* 139:452–467.
- Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, et al. 1998. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 51:1546–1554.
- Pham CT, de Silva R, Haik S, Verny M, Sachet A, Forette B, Lees A, Hauw JJ, Duyckaerts C. 2011. Tau-positive grains are constant in centenarians' hippocampus. *Neurobiol Aging* 32:1296–1303.
- Pilli M, Arko-Mensah J, Ponpuak M, Roberts E, Master S, Mandell MA, Dupont N, Ornatowski W, Jiang S, Bradfute SB, Bruun JA, Hansen TE, et al. 2012. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. *Immunity* 37:223–234.
- Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkerson R, Brown P, Ravenscroft T, van Blitterswijk M, Nicholson AM, DeTure M, Knopman DS, et al. 2015. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. *Acta Neuropathol* 130:77–92.
- Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, et al. 2011. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 134:2456–2477.
- Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, et al. 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72:257–268.
- Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, Yamanouchi H, Murayama S. 2004. Staging of argyrophilic grains: an age-associated tauopathy. *J Neuropathol Exp Neurol* 63: 911–918.
- Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleruche J, et al. 2008. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* 319:1668–1672.
- Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE. 2004. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet* 36:377–381.
- Williams KL, McCann EP, Fifita JA, Zhang K, Duncan EL, Leo PJ, Marshall M, Rowe DB, Nicholson GA, Blair IP. 2015. Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin. *Neurobiol Aging* 36:3334.e1–3334.e5.
- van der Zee J, Gijselink I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, Philtjens S, Vandenbulcke M, Sleegers K, Sieben A, Bäumer V, Maes G, et al. 2013. A pan-European study of the C9orf72 repeat associated with FTL: geographic prevalence, genomic instability, and intermediate repeats. *Hum Mutat* 34:363–373.
- van der Zee J, Van Langenhove T, Kovacs GG, Dillen L, Deschamps W, Engelborghs S, Matěj R, Vandenbulcke M, Sieben A, Derraut B, Smets K, Van Damme P, et al. 2014. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. *Acta Neuropathol* 128:397–410.